Samsung Biologics revenue and financials
₩1,277,000.00Change from previous close: −2.52%Absolute change: −₩33,000.00
In the fiscal year ended December 2025, Samsung Biologics reported revenue of ₩4.56T (+30.31% year over year). Net income was ₩1.78T, a net margin of 39.2%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +30.31%
- 2025 vs 2024
- Net income growth
- +64.71%
- 2025 vs 2024
- Net margin
- 39.2%
- 2024: 31.0%
Financial data
Amounts in millions of KRW; per-share values in KRW; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | 2,247,807 | 1,659,255 | 1,666,229 | 953,048 | 454,596 |
| Depreciation and amortization | 633,637 | 599,101 | 489,782 | 308,264 | 161,789 |
| Capital expenditure | -1,391,741 | -1,303,573 | -995,071 | -956,840 | -406,254 |
| Investing cash flow | -1,862,426 | -1,243,776 | -1,566,305 | -3,106,477 | -933,489 |
| Financing cash flow | -620,504 | -433,788 | -635,050 | 3,000,080 | 496,622 |
| Share repurchases | -92,013 | — | — | — | — |
| Debt issued | 85,000 | 1,129,659 | 803,500 | 805,653 | 698,356 |
| Debt repaid | -397,075 | -1,563,447 | -1,438,750 | -993,894 | -201,734 |
| Effect of exchange rates | -7,247 | 41,593 | 12,245 | -3,242 | 831 |
| Net change in cash | -242,370 | 23,284 | -522,882 | 843,409 | 18,560 |
| Free cash flow | 856,067 | 355,682 | 671,158 | -3,792 | 48,343 |
| Levered free cash flow | 515,493 | 66,655 | -446,653 | 21,978 | 62,860 |